GlaxoSmithKline
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine
- Conditions
- Neisseria MeningitidisHaemophilus Influenzae Type b
- Interventions
- Biological: GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis 792014 vaccineBiological: ActHIBBiological: PediarixBiological: PedvaxHIBBiological: PrevnarBiological: M-M-R IIBiological: Varivax
- First Posted Date
- 2006-02-10
- Last Posted Date
- 2018-08-24
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 4441
- Registration Number
- NCT00289783
- Locations
- 🇲🇽
GSK Investigational Site, Mexico, D.F., Mexico
Once-Daily Investigational Nasal Spray In Adults And Adolescents With Perennial Allergic Rhinitis (PAR)
- Conditions
- Rhinitis, Allergic, Perennial
- Interventions
- Drug: FFDrug: Placebo
- First Posted Date
- 2006-02-09
- Last Posted Date
- 2018-04-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 301
- Registration Number
- NCT00289198
- Locations
- 🇷🇺
GSK Investigational Site, Saint-Petersburg, Russian Federation
Assess the Immunogenicity & Safety of 2 Doses of Oral Live Attenuated Human Rota(HRV)Vaccine in Healthy Infants in India
- Conditions
- Infections, Rotavirus
- First Posted Date
- 2006-02-09
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 360
- Registration Number
- NCT00289172
- Locations
- 🇮🇳
GSK Investigational Site, Vellore,, India
Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants
- Conditions
- MalariaMalaria Vaccines
- Interventions
- Biological: Engerix-B®Biological: RTS,S/AS02DBiological: TETRActHib™
- First Posted Date
- 2006-02-09
- Last Posted Date
- 2020-10-29
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 340
- Registration Number
- NCT00289185
- Locations
- 🇹🇿
GSK Investigational Site, Dar-es-Salaam, Tanzania
US-licensed Combined Vaccine Against Tetanus & Diphtheria, Given With US-licensed Vaccine Against Meningococcal Disease
- Conditions
- TetanusAcellular PertussisDiphtheria
- Interventions
- Biological: Boostrix®Biological: Menactra™
- First Posted Date
- 2006-01-26
- Last Posted Date
- 2018-08-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1344
- Registration Number
- NCT00282295
- Locations
- 🇺🇸
GSK Investigational Site, West Jordan, Utah, United States
A Phase II, Open-Label Study Evaluating the Effect Of GW786034 In Subjects With Ovarian Cancer
- Conditions
- Neoplasms, OvarianOvarian CancerFallopian Tube CancerPeritoneal Cancer
- Interventions
- Drug: GW786034
- First Posted Date
- 2006-01-25
- Last Posted Date
- 2018-09-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 35
- Registration Number
- NCT00281632
- Locations
- 🇸🇬
GSK Investigational Site, Singapore, Singapore
SB-705498 Dental Pain Study After Tooth Extraction
- Conditions
- Toothache
- Interventions
- Drug: PlaceboDrug: SB705498 400 mgDrug: SB705498 1000 mgDrug: Co-Codamol
- First Posted Date
- 2006-01-25
- Last Posted Date
- 2019-01-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 145
- Registration Number
- NCT00281684
- Locations
- 🇬🇧
GSK Investigational Site, Manchester, United Kingdom
Effects Of GW679769 On Sleep Onset And Maintenance And Next Day Functioning In Subjects With Primary Insomnia
- Conditions
- Sleep Initiation and Maintenance DisordersInsomnia
- First Posted Date
- 2006-01-23
- Last Posted Date
- 2015-04-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 342
- Registration Number
- NCT00280423
- Locations
- 🇨🇦
GSK Investigational Site, Sainte-Foy, Quebec, Canada
Effects Of GW679769 On Sleep Onset And Maintenance,And Next Day Functioning In The Elderly And Non-elderly With Primary Insomnia
- Conditions
- InsomniaSleep Initiation and Maintenance Disorders
- First Posted Date
- 2006-01-23
- Last Posted Date
- 2015-04-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 122
- Registration Number
- NCT00280436
- Locations
- 🇺🇸
GSK Investigational Site, Fairfax, Virginia, United States
GW406381 In Patients With Peripheral Nerve Injury
- Conditions
- HyperalgesiaNeurodyniaPainTrauma
- First Posted Date
- 2006-01-19
- Last Posted Date
- 2009-02-23
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 40
- Registration Number
- NCT00279032
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom